Leonard Frank X

Officer at NVCR

Sold, on record
$13.3M
Dollars the filings state
Form 4 sales
30
Latest Jun 4, 2026
Form 144 notices
10
Proposed sales
Companies
1
Filed as an executive or holder

Companies

  • NVCRNovoCure LtdOfficer

Sales by reason

0
Routine
13
Plan not stated
5
No plan
12
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per year, every sale on record.

Sales chart range

Timeline

  1. 1 Form 4 sale NVCRUnusual
    Jun 2, 2025 2025

    Sold 30,196 shares at $17.50 ($528k)

    Leonard Frank X, EVP, Pres., Novocure Oncology

    10b5-1 planSold 15.2% of holdings ($3.5M position)168,452 shares left12x usual sizeFollows a Form 144Filing

  2. 2 Form 144 notice NVCRNotice
    Feb 27, 2026 +270 days

    Filed to sell 9,734 shares ($133k)

    Leonard Frank X, Officer

    No 10b5-1 plan3.9x usual sizeFiling

  3. 3 Form 144 notice NVCRNotice
    Mar 2, 2026 +3 days

    Filed to sell 7,232 shares ($98k)

    Leonard Frank X, Officer

    No 10b5-1 plan2.9x usual sizeFiling

  4. 4 Form 4 sale NVCRUnusual
    Mar 2, 2026 same day

    Sold 16,966 shares at $13.59 ($231k)

    Leonard Frank X, Chief Executive Officer

    No 10b5-1 planSold 4.6% of holdings ($5M position)349,400 shares left6.7x usual sizeFollows a Form 144Filing

  5. 5 Form 144 notice NVCRNotice
    Mar 4, 2026 +2 days

    Filed to sell 5,607 shares ($75k)

    Leonard Frank X, Officer

    No 10b5-1 plan0.6x usual sizeFiling

  6. 6 Form 4 sale NVCRNo plan
    Mar 4, 2026 same day

    Sold 5,607 shares at $13.31 ($75k)

    Leonard Frank X, Chief Executive Officer

    No 10b5-1 planSold 1.1% of holdings ($6.6M position)493,793 shares left0.4x usual sizeFollows a Form 144Filing

  7. 7 Form 144 notice NVCRNotice
    Jun 4, 2026 +92 days

    Filed to sell 34,273 shares ($615k)

    Leonard Frank X, Officer

    No 10b5-1 plan3.3x usual sizeFiling

  8. 8 Form 4 sale NVCRUnusual
    Jun 4, 2026 same day

    Sold 34,273 shares at $17.93 ($615k)

    Leonard Frank X, Chief Executive Officer

    No 10b5-1 planSold 6.9% of holdings ($8.9M position)459,520 shares left3.3x usual sizeFollows a Form 144Filing

Every transaction

Loading transactions…

Sales and notices (40)

Form 144 notices and Form 4 sales by Leonard Frank X
Source
Jun 4, 2026Jun 5, 2026NVCRChief Executive OfficerForm 4 sale34,273$615k6.9%UnusualSEC
Jun 4, 2026Jun 4, 2026NVCROfficerForm 144 notice34,273$615kNoticeSEC
Mar 4, 2026Mar 5, 2026NVCRChief Executive OfficerForm 4 sale5,607$75k1.1%No planSEC
Mar 4, 2026Mar 4, 2026NVCROfficerForm 144 notice5,607$75kNoticeSEC
Mar 2, 2026Mar 3, 2026NVCRChief Executive OfficerForm 4 sale16,966$231k4.6%UnusualSEC
Mar 2, 2026Mar 2, 2026NVCROfficerForm 144 notice7,232$98kNoticeSEC
Feb 27, 2026Feb 27, 2026NVCROfficerForm 144 notice9,734$133kNoticeSEC
Jun 2, 2025Jun 4, 2025NVCREVP, Pres., Novocure OncologyForm 4 sale30,196$528k15.2%UnusualSEC
Jun 2, 2025Jun 2, 2025NVCROfficerForm 144 notice30,196$577kNoticeSEC
Mar 3, 2025Mar 4, 2025NVCREVP, Pres., Novocure OncologyForm 4 sale2,527$47k1.7%No planSEC
Mar 3, 2025Mar 3, 2025NVCROfficerForm 144 notice2,527$47kNoticeSEC
Feb 28, 2025Mar 3, 2025NVCREVP, Pres., Novocure OncologyForm 4 sale15,036$296k9.3%UnusualSEC
Feb 28, 2025Feb 28, 2025NVCROfficerForm 144 notice2,770$51kNoticeSEC
Feb 27, 2025Feb 27, 2025NVCROfficerForm 144 notice12,266$246kNoticeSEC
Nov 1, 2024Nov 4, 2024NVCREVP, Pres., Novocure OncologyForm 4 sale598$10k0.4%No planSEC
Mar 4, 2024Mar 5, 2024NVCREVP, Pres., Novocure OncologyForm 4 sale2,519$40k1.5%No planSEC
Mar 4, 2024Mar 4, 2024NVCROfficerForm 144 notice840$13kNoticeSEC
Mar 1, 2024Mar 1, 2024NVCROfficerForm 144 notice1,679$27kNoticeSEC
Feb 28, 2024Feb 29, 2024NVCREVP, Pres., Novocure OncologyForm 4 sale2,078$34k1.3%No planSEC
Mar 7, 2023Mar 7, 2023NVCRPresident, CNS Cancers USForm 4 sale13,609$1M20.0%UnusualSEC
Mar 3, 2023Mar 6, 2023NVCRPresident, CNS Cancers USForm 4 sale2,903$223k4.1%Plan not statedSEC
Mar 2, 2023Mar 3, 2023NVCRPresident, CNS Cancers USForm 4 sale4,107$310k6.5%Plan not statedSEC
Mar 1, 2023Mar 2, 2023NVCRPresident, CNS Cancers USForm 4 sale1,684$129k2.6%Plan not statedSEC
Jan 5, 2023Jan 9, 2023NVCRPresident, CNS Cancers USForm 4 sale39,507$4.4M46.1%UnusualSEC
Oct 13, 2022Oct 17, 2022NVCRPresident, CNS Cancers USForm 4 sale6,754$513k13.4%UnusualSEC
Oct 6, 2022Oct 7, 2022NVCRPresident, CNS Cancers USForm 4 sale6,754$570k11.8%UnusualSEC
Sep 29, 2022Sep 30, 2022NVCRPresident, CNS Cancers USForm 4 sale6,754$522k10.6%UnusualSEC
Sep 22, 2022Sep 26, 2022NVCRPresident, CNS Cancers USForm 4 sale6,754$520k9.6%UnusualSEC
Sep 15, 2022Sep 19, 2022NVCRChief Development OfficerForm 4 sale12,271$1.1M14.8%UnusualSEC
Sep 9, 2022Sep 12, 2022NVCRChief Development OfficerForm 4 sale1,863$164k2.2%Plan not statedSEC
Sep 6, 2022Sep 7, 2022NVCRChief Development OfficerForm 4 sale1,384$109k1.6%Plan not statedSEC
Sep 2, 2022Sep 6, 2022NVCRChief Development OfficerForm 4 sale14,796$1.1M14.5%UnusualSEC
Aug 2, 2022Aug 3, 2022NVCRChief Development OfficerForm 4 sale414$29k0.4%Plan not statedSEC
Mar 8, 2022Mar 9, 2022NVCRChief Development OfficerForm 4 sale744$52k0.7%Plan not statedSEC
Mar 4, 2022Mar 7, 2022NVCRChief Development OfficerForm 4 sale1,485$108k1.4%Plan not statedSEC
Sep 2, 2021Sep 7, 2021NVCRChief Development OfficerForm 4 sale540$75k0.6%Plan not statedSEC
Aug 3, 2021Aug 4, 2021NVCRChief Development OfficerForm 4 sale1,041$156k1.2%Plan not statedSEC
Mar 8, 2021Mar 10, 2021NVCRChief Development OfficerForm 4 sale765$100k0.8%Plan not statedSEC
Mar 4, 2021Mar 8, 2021NVCRChief Development OfficerForm 4 sale567$78k0.6%Plan not statedSEC
Mar 2, 2021Mar 4, 2021NVCRChief Development OfficerForm 4 sale430$65k0.5%Plan not statedSEC